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Death receptor-mediated cell death  
Induction of cell death plays a crucial role in morphogenesis, homeostasis, immune tolerance 
and surveillance and chemotherapy. Supernumerary, damaged, transformed, or infected cells 
can be eliminated through intrinsic or extrinsic cell death programs. The induction of the 
extrinsic signal occurs when cytokines (i.e., CD95L, TRAIL, TNF- ) present in serum or 
anchored in immune cells (e.g., T-lymphocytes, natural killer cells) bind to their respective 
death receptors, namely CD95 (also called APO-1 or Fas), DR4 and DR5 or TNF-R1. 
Interaction with the ligand orchestrates aggregation and conformational alteration of the death 
receptors, whose intracellular domains recruit adaptor proteins (i.e., TRADD, FADD), which 
in turn drive, through protein/protein interactions, the induction of caspases evoking the death 
program.  
 
Plasma membrane and “death receptor” signaling pathways  
The extensive characterization of the protein/protein interactions promoting the ignition of the 
apoptotic signal, led to underestimate the role played by the lipid bilayer plasma membrane in 
the signaling induced by death receptors. In this regard, death receptors are anchored into a 3-
D support, the plasma membrane, which exhibits a complex structure and exerts constraints 
affecting receptor motility, aggregation, conformation and consequently signaling. Recent 
evidences established that not only the lipid composition of the membrane bilayer, but also 
the partition of the death receptors into subdomains designated lipid rafts, detergent-resistant 
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membranes (DRMs), or merely microdomains may affect the transmission of the apoptotic 
pathway. For instance, distribution of CD95 into lipid rafts dramatically enhances the 
induction of the signal [1-6]. More strikingly, not only the ligand fixation is able to 
redistribute CD95 into lipid rafts, but also different anti-tumoral agents have been reported to 
achieve the partition of CD95 into large platforms constituted of aggregated lipid rafts [2, 7-
12]. It is noteworthy that the reorganization of CD95 into DRMs can occur independently of 
its ligand upon addition of certain chemotherapeutic drugs (e.g., rituximab [13], resveratrol 
[9, 14], edelfosine [7, 11], aplidin [15, 16], perifosine [15, 16], cisplatin [12]). The molecular 
mechanisms that underlie this process remain to be elucidated. Nevertheless, the current 
evidence let us to envision that intracellular signal(s) or modulation of the plasma membrane 
biophysical properties mimic the death cytokine-driven initial events [17].  
It is noteworthy that designation of these receptors as “death receptors” originated 
from initial studies that were seeking for apoptotic inducers [18, 19]. However, this 
appellation leads to a misunderstanding since all death receptors are able to induce non-
apoptotic signals that, in certain context, promote carcinogenesis [20-23]. While theoretically 
speaking, decrease in the apoptotic threshold has been reported to switch the CD95 signal 
from a non-apoptotic to an apoptotic signaling pathway [24-26], it remains to identify the 
molecular mechanism(s) underlying this phenomenon. Endocytosis of CD95 may reduce the 
apoptotic threshold and thereby, to discriminate between apoptosis and non-apoptosis 
signaling. Indeed, cells harboring a mutation in the AP-2-binding motif of CD95 (e.g, Y291F) 
were not only unable to internalize the death receptor and to transmit the apoptotic signal, but 
they continued to induce non-apoptotic signals in the presence of CD95L [27]. In this topic 
issue, Milosavljenic and colleagues reported that endocytosis relies on the forces applied on 
the membrane and thus, on the composition of the membrane itself. Consequently, we may 
envision that the plasma membrane composition, which diverges between normal and tumor 
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cells, controls the fate of the CD95 signal, even if the role of endocytosis in death receptor 
signaling remains controversial [28, 29]. Likewise, the partition of CD95 into aggregated lipid 
rafts, whose micrometer-sized structure accumulates and/or excludes critical death 
modulators, may alternatively contribute to modulating the apoptotic threshold and thus, the 
cell fate. The partition of death receptors together with downstream apoptotic signaling 
molecules in aggregated DRMs [15, 16, 30-32] has led to the emerging concept of “liquid-
ordered” plasma membrane platform designated as “cluster of apoptotic signaling molecule-
enriched rafts” (CASMER) [33]. These CASMERs may reduce the apoptotic signal threshold 
by stabilizing protein/protein interactions and thereby, catalyze the transmission of the 
apoptotic signal [33].  
 
Biophysical properties of the plasma membrane and “death receptor” signaling pathways  
Another parameter regulating the biophysical properties of plasma membrane and its 
composition is the intracellular pH, which in turn alters the induction of the apoptotic signal 
induced upon death receptor engagement. Indeed, reduction of the intracellular pH not only 
modulates the plasma membrane composition by activating acidic sphingomyelinase, which 
in turn generates ceramides, but also promotes protonation of the lipid polar heads present in 
the inner leaflet. This latter effect reduces membrane packing and tension, which both 
influence drug permeation and membrane endocytosis, affecting the amounts of 
chemotherapeutic drugs retained in tumor cells and the death receptor signaling, respectively. 
In addition, numerous pollutants alter the biophysical properties of the plasma membrane 
through the production of reactive oxygen species (ROS), which in turn enhance lipid 
peroxidation [34], activate acid sphingomyelinase [35], and modulate gene expression 
involved in lipid metabolism, and thus modify plasma membrane composition.  
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In agreement with these notions, the fine regulation of ceramide synthesis (balance 
between hydrolysis of sphingomyelin and de novo biosynthesis) should be an essential player 
in promoting or impeding both immune response (death receptor signaling) and chemotherapy 
outcome (death receptor signaling and drug retention). In this regard, numerous patents cover 
the association of the apoptotic cytokines (i.e., CD95L, TRAIL, TNF) or chemotherapeutic 
regimens with ceramide or its derivatives in order to re-sensitize malignant cells to death [36-
43]. Nevertheless, it remains to define the appropriate length of the fatty acid linked to the 
sphingosine backbone, that will structurally impact the plasma membrane conformation in 
order to enhance endocytosis, accumulate drugs inside tumor cells, and/or catalyze the 
apoptotic signal triggered by death receptors.  
This thematic issue tempts to provide some new insight into the potential 
chemotherapeutical roles of CD95 and TRAIL-R signaling pathways and their modulation by 
the biophysical properties of the plasma membrane.  
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